Madrigal Pharmaceuticals (MDGL) Competitors

Biogen (NASDAQ:BIIB) and Madrigal Pharmaceuticals (NASDAQ:MDGL) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, media sentiment, analyst recommendations, dividends and earnings.

Do insiders and institutionals believe in BIIB or MDGL?

87.9% of Biogen shares are held by institutional investors. Comparatively, 98.5% of Madrigal Pharmaceuticals shares are held by institutional investors. 0.2% of Biogen shares are held by insiders. Comparatively, 21.5% of Madrigal Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Is BIIB or MDGL more profitable?

Biogen has a net margin of 15.31% compared to Madrigal Pharmaceuticals' net margin of -54.68%. Biogen's return on equity of 13.85% beat Madrigal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biogen	15.31%	13.85%	8.32%
Madrigal Pharmaceuticals	-54.68%	-38.38%	-27.32%

Which has stronger valuation and earnings, BIIB or MDGL?

Biogen has higher revenue and earnings than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biogen	$9.68B	2.04	$1.63B	$10.46	12.87
Madrigal Pharmaceuticals	$515.55M	16.09	-$465.89M	-$12.85	-29.07

Which has more volatility & risk, BIIB or MDGL?

Biogen has a beta of 0.13, indicating that its share price is 87% less volatile than the S&P 500. Comparatively, Madrigal Pharmaceuticals has a beta of -1.02, indicating that its share price is 202% less volatile than the S&P 500.

Does the media refer more to BIIB or MDGL?

In the previous week, Biogen had 3 more articles in the media than Madrigal Pharmaceuticals. MarketBeat recorded 37 mentions for Biogen and 34 mentions for Madrigal Pharmaceuticals. Biogen's average media sentiment score of 0.82 beat Madrigal Pharmaceuticals' score of 0.60 indicating that Biogen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biogen	22 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Positive
Madrigal Pharmaceuticals	12 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Positive

Do analysts recommend BIIB or MDGL?

Biogen currently has a consensus target price of $185.63, indicating a potential upside of 37.89%. Madrigal Pharmaceuticals has a consensus target price of $439.71, indicating a potential upside of 17.71%. Given Biogen's higher possible upside, analysts plainly believe Biogen is more favorable than Madrigal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biogen	0 Sell rating(s)	21 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.34
Madrigal Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.88

Summary

Biogen beats Madrigal Pharmaceuticals on 12 of the 16 factors compared between the two stocks.